A total of 50 patients with non-Hodgkin lymphoma were treated on the open label single-arm, dose-escalation study of SGN-40. Cohorts of patients received escalating doses of SGN-40 ranging from two milligrams per kilogram (mg/kg) to 8mg/kg. The median age was 62 years and patients had received a median of three prior therapies.
Out of 48 patients treated with SGN-40 who were evaluable for response across all dose levels, six patients achieved objective responses, including one complete response and five partial responses. A total of 13 patients had stable disease and 29 had progressive disease. Of the 22 patients on the trial with diffuse large B-cell lymphoma (DLBCL), a more aggressive type of non-Hodgkin lymphoma, four achieved an objective response. Overall, SGN-40 was well-tolerated with no maximum tolerated dose identified.
SGN-40 is a humanized monoclonal antibody being developed under a worldwide collaboration agreement with Genentech.
Thomas Reynolds, chief medical officer of Seattle Genetics, said: The data support our ongoing development plan with Genentech, which includes multiple clinical trials of SGN-40 both as a single agent and in combination with standard treatment regimens for patients with DLBCL, the most common type of non-Hodgkin lymphoma.